An advertisement for Mitigo with the taglines "Relief with reassurance" and "FDA-approved Mitigo delivers essential levels of purity consistency and compatibility for reliable pain relief". On the right side of the image there is a close-up of the back of a person's body with their back facing the viewer. On the left side there are two small orange bottles of Mitigo (presumably) as well as the Mitigo logo. The background is black with text is in white and green.
Description
Type 
Category
Source 1 of 4
-
Date
2010
Collection
-
Date
2014
Collection
-
Date
2010
Collection
-
Date
2014
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
![Information about NUCYNTA ER. It is titled "NUCYNTA ER: better GI tolerability than oxycodone CR in a 1-year safety study". There is a bar graph at the center of the image titled "Incidence of the treatment-emergent adverse events reported [...] treatment group in a 52-week study (osteoarthritis[...]". The x-axis values between 0 and 40. The y-axis has a number of adverse events. The graph shows that NUCYNTA ER had a lower incidence of adverse events than Oxycodone for nausea vomiting constipation dizziness and skin pruritus (itching). It shows that Oxycodone had a lower incidence of adverse events for diarrhea dry mouth somnolence and headache. They show equal values for fatigue. The bars for nausea vomiting and constipation are at the top of the graph and they are highlighted in brighter colors. An arrow points to these bars and is labeled "50% lower incidence of nausea vomiting and constipation vs. oxycodone CR". <br /><br />The image also shows a red side bar with the NUCYNTA ER logo and selected important safety information.](https://oida-resources-images.azureedge.net/public/full/bdae85ed-5038-4ac0-8738-b5232296aa03.jpg)
